The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of "second adjuvant" therapy with BRAF/MEK inhibitors after resection of recurrent melanoma following adjuvant PD-1–based immunotherapy.
 
Amelia M. Taylor
No Relationships to Disclose
 
Claire Galea
No Relationships to Disclose
 
Serigne N. Lo
No Relationships to Disclose
 
Florentia Dimitriou
Honoraria - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Sun Pharma
 
Sarah Jacques
No Relationships to Disclose
 
Clara Allayous
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Hui-Ling Yeoh
No Relationships to Disclose
 
Julia M. Ressler
Speakers' Bureau - Novartis
Research Funding - Amgen
Travel, Accommodations, Expenses - Pierre Fabre
 
Katharina C. Kähler
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Lucia Festino
No Relationships to Disclose
 
Julia Katharina Schwarze
Honoraria - Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; MSD Belgium
 
Alexandre M. Wicky
No Relationships to Disclose
 
Joanna Placzke
No Relationships to Disclose
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Catalyst Pharmaceuticals; Iovance Biotherapeutics; Janssen; Merck; Mosaic ImmunoEngineering; Novartis; Oncosec; Pfizer; Targovax
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Lisa Zimmer
Stock and Other Ownership Interests - Bayer
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi; Sun Pharma
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Other Relationship - Avantis Medical Systems
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Merck Serono; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; Provectus; QBiotics; Regeneron; Skyline Diagnostics
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche